Trial Profile
A Phase 3, Open-Label Study Evaluating the Efficacy and Safety of Liprotamase in Subjects With Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 21 Jul 2022
Price :
$35
*
At a glance
- Drugs Liprotamase (Primary)
- Indications Cystic fibrosis; Exocrine pancreatic insufficiency
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms SIMPLICITY
- Sponsors Anthera Pharmaceuticals
- 12 Mar 2018 According to an Anthera Pharmaceuticals media release, based on the data from RESULT trial the company is discontinuing further clinical development of Sollpura including the 20-Week Extension Period of RESULT, the SIMPLICITY study and the EASY study.
- 12 Mar 2018 Status changed from active, no longer recruiting to discontinued, as reported in an Anthera Pharmaceuticals Media Release.
- 12 Jan 2018 Planned End Date changed from 1 Jun 2017 to 1 Dec 2019.